Title: A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer
This study is for patients who have been diagnosed with lung cancer. Even with an operation and adjuvant (after-surgery) chemotherapy, there is still a risk that your cancer may recur (come back). Research is being done to try to find additional ways to prevent cancer from recurring.
The investigational anti-cancer treatment (vaccine) that is being studied is based upon immunization. It teaches your own body (its immune system) to fight the cancer in the same way that it fights an infection from germs or viruses. In this way, it is hoped that any recurrence of cancer will be delayed or even prevented. The purpose of this clinical study is to see whether this type of anti-cancer treatment works, and, if it does, to measure its effectiveness with more precision.
However, this new anti-cancer treatment cannot be applied to all types of lung cancers. To be eligible for this study, your cancer needs to have certain characteristics: it must produce a protein called MAGE-A3. Only about 35% of people with lung cancer produce the MAGE-A3 protein and this production will be checked to see if you are one of those who might benefit. If your cancer does not contain MAGE-A3, you will not be eligible to be in this research.
Have Any Questions? Please contact:
Clinical Research Coordinator
LHSC Victoria Hospital
(519) 685-8500 ext 75685